Fate Therapeutics announced this week that Rudolf Jaenisch, founding member of the Whitehead Institute for Biomedical Research and a professor of biology at the Massachusetts Institute of Technology, has joined the company's team of scientific founders.
In connection with the appointment, Fate Therapeutics also announced this week that it has completed an exclusive license agreement with the Whitehead Institute covering discoveries in the area of cell reprogramming.